Initial treatment of pediatric MS or clinically isolated syndrome (CIS) with newer disease-modifying therapies (DMTs) is associated with better control of disease activity compared with treatment with injectables, researchers have reported.
News News Daily digests from key neurology conferences, written by on-site medical journalists.